NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

Novartis reported Q3 2026 core EPS of $2.46, up 9% year over year and 9.3% above the $2.25 consensus, while revenue rose 4% to $14.52 billion but missed estimates by 0.2%. Core operating income increased 11% to $6.04 billion, and the company raised its 2026 core operating income outlook from a low-single-digit decline to flat-to-low-single-digit growth, maintaining its low-single-digit sales-growth outlook. Strong sales at several priority brands and product milestones were offset by generic erosion and late-stage trial failures for del-desiran and pelacarsen.

Analysis

The earnings signal is better for operating leverage than for demand: core operating income improved while sales guidance did not, implying the upgraded outlook depends materially on mix and productivity rather than a broad acceleration in the top line. That supports near-term earnings resilience, but leaves less room for execution slippage if growth brands slow or generic erosion broadens. The EPS beat is also lower quality than the headline suggests because a lower share count contributed.

The key portfolio question is whether newer brands can outrun the runoff. Kisqali, Kesimpta and Scemblix provide evidence of commercial traction, but individual sales misses for Kisqali, Pluvicto and Leqvio caution against extrapolating headline growth rates without prescription, capacity and access data. Entresto’s erosion is already a meaningful drag; Lutathera adds a separate patent-litigation catalyst that could accelerate erosion if the appeal fails. Over 6–18 months, launch execution and replacement-product growth matter more than this quarter’s beat.

The positive pre-market reaction risks over-weighting guidance and under-weighting pipeline attrition. Failed pelacarsen results are a negative for Ionis’s partnered asset, but do not establish an equivalent impairment to its broader pipeline; the article supplies no economics for quantifying the impact. Likewise, Leqvio’s relationship with Alnylam is not enough to infer a material ALNY earnings read-through without royalty and sales terms. Roche’s Xolair exposure is a limited, unquantified co-promotion read-through, not a basis for a Roche-wide thesis.

Key Decisions for Investors

• NVS: avoid chasing the pre-market pop. Consider a measured long only if shares hold the post-open reaction and management commentary supports the raised core operating-income range; this is an earnings-quality/mix thesis, not a top-line acceleration call. Reassess if guidance is cut, priority-brand demand decelerates, or generic erosion outpaces productivity.
• Over the next 1–3 months, monitor Kisqali, Kesimpta, Scemblix and Pluvicto demand, plus operating costs and share-count effects. Repeated sales misses or a widening gap between operating-income growth and revenue growth would weaken the long case.
• Lutathera: treat the appeal outcome as a defined downside catalyst rather than extrapolating its current growth. A loss that removes effective protection could bring generic competition forward; verify the ruling and launch timing before positioning.
• IONS: do not short solely on pelacarsen’s failed endpoint. Revisit only after assessing the company’s updated pipeline, remaining partnered economics and any guidance changes; the supplied information does not quantify the lost value.
• ALNY and ROP: no actionable read-through from the Leqvio and Xolair references alone. Verify contractual economics and each company’s reported product contribution before trading either name.